Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Bezuclastinib + Sunitinib

Stage Registration

Sponsor Cogent Biosciences

Route oral

Modality small molecule

Class KIT type I TKI plus type II TKI combination

Mechanism selective type 1 KIT inhibitor combined with sunitinib (type 2)

Target KIT (TEC-0117)

Target KIT exon 17/18 (activation loop)

Sources

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11500

Patients were randomized 1:1 to bezuclastinib 600 mg once daily (QD) + sunitinib 37.5 mg QD (n=204) or sunitinib 37.5 mg QD (n=209) ... mPFS was 16.5 months (95% CI, 13.8-19.2) for the combination vs 9.2 months (95% CI, 7.2-11.0) for monotherapy. ORR significantly improved with the combination vs monotherapy (46% vs 26%

J Clin Oncol 44(16_suppl) abstract 11500 (ASCO 2026), Peak (NCT05208047); congress abstract, preliminary

company_release, as of 2026-11-07

https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0

assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 ... Hypertension (29.4% vs. 27.4%), Neutropenia (15.2% vs. 15.4%), ALT/AST increased (10.8% vs. 1.4%), Anemia (9.3% vs. 4.8%) and Diarrhea (7.8% vs. 7.2%). 7.4% of patients on the bezuclastinib combination and 3.8% of patients on sunitinib monotherapy discontinued study treatment(s) due to treatment related adverse events.

Cogent Biosciences release 05.28.2026

company_release, as of 2026-11-07

https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3

Median PFS2 was not reached versus 21 months (HR=0.57, 95% CI: 0.41-0.78)

Cogent Biosciences release, ASCO 2026

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05208047

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Peak

Registry NCT05208047

Phase Phase 3

Status Recruiting

Enrollment 482

Start 2022-04-14

Primary completion 2025-09-30

Study completion 2030-01

Catalyst Primary completion. 09.30.2025. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst FDA PDUFA target action date (GIST, with sunitinib). 11.30.2026. Company-stated goal date, not a promise of action.

Bezuclastinib 600 mg + sunitinib 37.5 mg

Dose 600 mg + 37.5 mg

Regimen both once daily, continuous

Comparator sunitinib 37.5 mg

Population GIST after imatinib (n = 204)

Estimand ITT

median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025

progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025

objective response rate (BICR): 46%, data cutoff 09.30.2025

grade 3 or higher ALT/AST increased: 10.8%, data cutoff 09.30.2025

discontinued for treatment-related adverse events: 7.4%, data cutoff 09.30.2025

PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update

Sunitinib 37.5 mg continuous

Dose 37.5 mg

Regimen once daily, continuous

Population GIST after imatinib (n = 209)

Estimand ITT

median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025

objective response rate (BICR): 26%, data cutoff 09.30.2025

grade 3 or higher ALT/AST increased: 1.4%, data cutoff 09.30.2025

discontinued for treatment-related adverse events: 3.8%, data cutoff 09.30.2025